Hims & Hers: A High-Risk Bet

Hims & Hers Health, Inc. (HIMS) has been upgraded to a speculative buy despite a 20% post-Q2 earnings decline, as management reaffirmed its FY 2025 revenue guidance of $725 million, largely due to robust demand for personalized compounded GLP-1s. This positive outlook comes despite significant headwinds, including the termination of its Novo Nordisk partnership, which reduced subscriber book value by $40 million and average revenue per subscriber, alongside pressures in the sexual health segment and negative Q2 operating cash flow. The primary risk remains the regulatory uncertainty and ongoing litigations surrounding compounded GLP-1s, which could severely impact the company's revenue if banned.

Analysis

Hims & Hers Health, Inc. (HIMS) presents a high-risk, speculative investment profile following a 20% stock decline after its Q2 earnings release. The central pillar of the bull case is management's reaffirmation of its $725 million revenue guidance for FY 2025, which hinges critically on sustained high demand for its personalized compounded GLP-1 weight loss treatments. This outlook persists despite significant operational headwinds, most notably the termination of a partnership with Novo Nordisk, which directly contributed to a $40 million reduction in the subscriber book to $190 million and a drop in average revenue per subscriber from $84 to $74. The company also faces pressure in its sexual health segment, increased marketing costs absorbing 40% of revenue, and negative Q2 operating cash flow driven by working capital investments. The primary and most substantial risk factor is regulatory; the company's core weight loss revenue stream is vulnerable to adverse FDA rulings or litigation outcomes concerning compounded pharmaceuticals. While management projects a return to positive free cash flow in the second half of 2025, aided by a projected $50 million revenue contribution from the ZAVA acquisition, the market's skepticism is reflected in a high 30% short interest.

Key Decisions for Investors

• Consider a speculative long position for the second half of 2025, based on management's reaffirmed guidance, but acknowledge this is a high-risk trade contingent on the continued legality of its GLP-1 offerings.
• Closely monitor all regulatory news from the FDA and legal developments related to compounded drugs, as any negative ruling presents a direct and material threat to the company's primary revenue driver.
• Scrutinize upcoming quarterly results for evidence of a rebound in the weight loss subscriber base, stabilization of average revenue per subscriber, and a return to positive free cash flow generation as guided by management.
• Be aware that the high 30% short interest represents both a significant risk of continued selling pressure and the potential for a short squeeze if the company successfully executes its strategy and mitigates regulatory threats.